Welcome to our dedicated page for Medexus Pharmace news (Ticker: MEDXF), a resource for investors and traders seeking the latest updates and insights on Medexus Pharmace stock.
Medexus Pharms Inc (MEDXF), referred to in its disclosures as Medexus Pharmaceuticals, generates a steady flow of news related to its specialty pharmaceutical business in North America. Investors following MEDXF news can see updates on hematology and hematology-oncology products, as well as allergy, dermatology, and rheumatology therapies that form the company’s core portfolio.
Many Medexus news releases focus on GRAFAPEX (treosulfan) for Injection, an alkylating agent used as part of a preparative regimen for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia or myelodysplastic syndrome. The company reports on FDA approval, Orphan Drug Designation, US commercial launch timing, and key reimbursement milestones such as CMS New Technology Add-On Payment (NTAP) approval, transitional pass-through status, and assignment of a permanent HCPCS Level II "J code". These items provide insight into how Medexus is building its hematology-oncology franchise in the United States.
MEDXF news also covers quarterly and annual financial results, including net revenue, net income, Adjusted EBITDA, and product-level performance for GRAFAPEX, Trecondyv, IXINITY, Rupall, Rasuvo, Metoject, and Gleolan. The company uses these releases to discuss unit demand trends, the impact of generic competition on products such as Rupall, and portfolio dynamics across the United States and Canada.
Additional news topics include financing and capital allocation decisions, such as new senior secured credit facilities with National Bank of Canada, repayment of prior credit agreements, and the launch or renewal of a normal course issuer bid (NCIB) for Medexus common shares on the Toronto Stock Exchange. Governance-related items, including annual meetings of shareholders, director elections, and auditor appointments, are also reported.
For anyone tracking MEDXF, this news stream offers detailed information on product launches, regulatory and reimbursement milestones, financial performance, credit arrangements, and share repurchase activity. Bookmarking the Medexus news feed on Stock Titan can help investors and researchers follow how the company’s North American specialty pharmaceutical platform evolves over time.
Medexus Pharmaceuticals will present at the Q4 Investor Summit virtually on November 17, 2021, at 8:00 AM ET. CEO Ken d’Entremont and CFO Marcel Konrad will discuss the company’s innovative solutions in rare disease treatments. Interested investors can participate in one-on-one meetings throughout the conference. The summit connects small cap and microcap companies with over 800 investors, offering a platform to engage with potential stakeholders. For more details on the event and to register, visit www.investorsummitgroup.com.
Medexus Pharmaceuticals has appointed Ian C. Wildgoose Brown as the new general counsel and corporate secretary, effective immediately. With over a decade of legal expertise and experience in corporate transactions, he aims to strengthen the company’s commercial platform. Ken d’Entremont, CEO, expressed confidence in Wildgoose Brown's ability to contribute to growth through mergers and acquisitions. Medexus specializes in innovative treatments for rare diseases and holds a strong North American commercial presence.
Medexus Pharmaceuticals plans a conference call on November 11, 2021, at 8:00 AM ET to discuss its fiscal 2022 Q2 financial results ending September 30, 2021. Financial statements will be filed after the market closes on November 10, 2021. Investors can join via telephone or webcast. Medexus is recognized for its innovative treatments in rare diseases and aims for growth through its established product portfolio, including Rasuvo™, IXINITY®, and Rupall®.
Medexus Pharmaceuticals announced that the FDA granted a Type A meeting to medac GmbH for treosulfan, a drug intended for patients undergoing allogeneic hematopoietic stem cell transplantation. The meeting is scheduled for November 23, 2021. This follows a Complete Response Letter from the FDA received on August 3, 2021, regarding treosulfan's New Drug Application, indicating the need for additional data. CEO Ken d’Entremont expressed optimism about treosulfan's potential in the U.S. market, noting that the leading product, busulfan, achieved US$126M in sales before genericization.
Medexus Pharmaceuticals Inc. (OTCQX: MEDXF) will present at the Benzinga Global Small Cap Conference on October 28, 2021, at 3:00 pm ET. CEO Ken d’Entremont and CFO Marcel Konrad will lead the presentation. Investors can register for a free spectator pass here. The conference aims to connect small-cap companies with investors and includes educational modules on small-cap investing.
Medexus Pharmaceuticals has commenced its first commercial shipment of Trecondyv® in Canada following a Notice of Compliance from Health Canada on June 28, 2021. Trecondyv® is a bifunctional alkylating agent intended for patients undergoing allogeneic hematopoietic stem cell transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. The company aims to capitalize on positive market responses and anticipates rapid sales growth. Additionally, Medexus will issue shares instead of cash for a $1.25 million interest payment on its convertible debentures, focusing on preserving cash and sustaining its balance sheet.
Medexus Pharmaceuticals Inc. (OTCQX: MEDXF) held its annual and special meeting of shareholders on September 16, 2021, where all proposed directors were elected for the upcoming term.
Key voting results include:
- Peter van der Velden: 97.31% votes in favor
- Ken d’Entremont: 98.48% votes in favor
- Michael Mueller: 96.76% votes in favor
- Benoit Gravel: 97.76% votes in favor
- Stephen Nelson: 97.77% votes in favor
- Adele M. Gulfo: 98.05% votes in favor
Additionally, shareholders re-appointed PricewaterhouseCoopers LLP as auditors and approved amendments to the company's by-law and equity incentive plan.
Medexus Pharmaceuticals will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. CEO Ken d’Entremont and CFO Marcel Konrad will share insights during the event, with an on-demand presentation available from September 13 at 7:00 AM ET. This conference is a key opportunity for Medexus to engage with the investor community. Medexus focuses on innovative treatments for rare diseases, including products like Rasuvo™, IXINITY®, and Rupall®.
Medexus Pharmaceuticals reported Q1 fiscal 2022 revenue of $17.3 million, down from $20 million a year ago, mainly due to decreased IXINITY® sales as clients worked through existing inventory. However, patient demand for IXINITY® grew 25.3%. Adjusted EBITDA dropped to $(4.9) million and net loss rose to $(6.6) million. Notably, Rupall™ showed strong growth with a 44.4% increase in unit demand. The company anticipates improvements as inventory levels normalize.
Medexus Pharmaceuticals has completed enrollment in its Phase 4 Clinical Trial for IXINITY®, targeting label expansion for pediatric hemophilia B patients under 12 years. The trial's results could potentially allow the use of IXINITY® in younger patients, currently approved for ages 12 and older. Completion is expected by June 2022, with an FDA data submission anticipated by the end of 2022. The U.S. hemophilia B market is valued over $1 billion, presenting significant opportunities for Medexus if label expansion is successful.